ArticleJournal of cancer research and clinical oncology2011
RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration.
Article in Journal of cancer research and clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- Cullin1 regulates proliferation, migration and invasion of glioma cells.Medical oncology (Northwood, London, England) · 2014Trial
- Curcumin-Induced Molecular Mechanisms in U-87 MG Glioblastoma Cells: Insights from Global Gene Expression Profiling.Molecules (Basel, Switzerland) · 2025Article
- Assessment of differentially methylated loci in individuals with end-stage kidney disease attributed to diabetic kidney disease: an exploratory study.Clinical epigenetics · 2021Article
- Article
- PIWI-interacting RNAs and PIWI proteins in glioma: molecular pathogenesis and role as biomarkers.Cell communication and signaling : CCS · 2020Review
- lncRNA MT1JP Suppresses Biological Activities of Breast Cancer Cells in vitro and in vivo by Regulating the miRNA-214/RUNX3 Axis.OncoTargets and therapy · 2020Article
- Relationship between expression of XRCC1 and tumor proliferation, migration, invasion, and angiogenesis in glioma.Investigational new drugs · 2019Article
- Inactivation of RUNX3 protein expression in tongue squamous cell carcinoma and its association with clinicopathological characteristics.Molecular medicine reports · 2019Article
- Oncosuppressive Role of RUNX3 in Human Astrocytomas.Journal of oncology · 2019Article
- RUNX3 inhibits glioma survival and invasion via suppression of the β-catenin/TCF-4 signaling pathway.Journal of neuro-oncology · 2018Review
- Emerging role of RUNX3 in the regulation of tumor microenvironment.BMB reports · 2018Review
- Potential Epigenetic-Based Therapeutic Targets for Glioma.Frontiers in molecular neuroscience · 2018Review
- MiR-19 regulates the proliferation and invasion of glioma by RUNX3 via β-catenin/Tcf-4 signaling.Oncotarget · 2017Article
- Runx3 is a key modulator during the epithelial-mesenchymal transition of alveolar type II cells in animal models of BPD.International journal of molecular medicine · 2017Article
- RUNX3 is down-regulated in glioma by Myc-regulated miR-4295.Journal of cellular and molecular medicine · 2016Article
- Decreased expression of CHIP leads to increased angiogenesis via VEGF-VEGFR2 pathway and poor prognosis in human renal cell carcinoma.Scientific reports · 2015Article
- BRMS1 suppresses glioma progression by regulating invasion, migration and adhesion of glioma cells.PloS one · 2014Article
- Article
- Article
- RUNX3 is a prognostic marker and potential therapeutic target in human breast cancer.Journal of cancer research and clinical oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study is to investigate whether the expression of RUNX3 is related to the development of glioma, and the role of RUNX3 in glioma cells growth, invasion and migration.
methodsWe analyzed the protein expression of RUNX3 by immunohistochemistry in 188 glioma tissues, 8 normal brain tissues and 8 tumor adjacent normal brain tissues using tissue microarray technique. We studied whether RUNX3 restoration can suppress glioma cells growth, invasion and migration by performing MTT cell proliferation assay, matrigel cell invasion assay, wound-healing assay and migration assay. We also detected MMP-2 protein expression and enzyme activity by western blot analysis and gelatin zymography.
resultsWe found that RUNX3 expression was decreased in benign tumor and malignant tumor compared with tumor adjacent normal brain tissue (P < 0.01 and P < 0.05, respectively). We did not find any correlation between RUNX3 expression and clinicopathological parameters. In addition, we demonstrated that re-expression of RUNX3 in glioma cells resulted in significantly inhibited cell invasion and migration abilities. This reduced cell invasion and migration abilities were due to MMP-2 protein expression and enzyme activity suppression after RUNX3 restoration.
conclusionsOur data indicated that RUNX3 expression is significantly decreased in human glioma, and targeting of the RUNX3 pathway may constitute a potential treatment modality for glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.